CATX Logo

Perspective Therapeutics, Inc. (CATX) 

NYSE
Market Cap
$192.62M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
6 of 960
Rank in Industry
1 of 120

Largest Insider Buys in Sector

CATX Stock Price History Chart

CATX Stock Performance

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly …

Insider Activity of Perspective Therapeutics, Inc.

Over the last 12 months, insiders at Perspective Therapeutics, Inc. have bought $58.43M and sold $0 worth of Perspective Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Perspective Therapeutics, Inc. have bought $58.43M and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Lantheus Alpha Therapy, LLC (10 percent owner) — $57.41M. Williamson Robert F III (director) — $333,390. Spoor Johan M. (CEO) — $248,030.

The last purchase of 8,000 shares for transaction amount of $30,132 was made by Spoor Johan M. (CEO) on 2024‑12‑04.

List of Insider Buy and Sell Transactions, Perspective Therapeutics, Inc.

2024-12-04PurchaseCEO
8,000
0.0119%
$3.77$30,132-6.20%
2024-12-04Purchasedirector
25,975
0.0396%
$3.85$100,004-6.20%
2024-11-25Purchasedirector
6,266
0.0078%
$3.64$22,814+0.68%
2024-11-25PurchaseCEO
26,500
0.0342%
$3.79$100,468+0.68%
2024-11-25PurchaseChief Financial Officer
12,829
0.0167%
$3.82$48,974+0.68%
2024-06-17PurchaseChief Financial Officer
1,800
0.006%
$9.81$17,667+18.42%
2024-06-14Purchasedirector
4,587
0.017%
$10.90$49,990+14.30%
2024-06-13PurchaseCEO
100,000
0.0399%
$1.17$117,430+5.39%
2024-06-03Purchasedirector
34,246
0.017%
$1.46$49,992-10.44%
2024-05-31Purchasedirector
55,000
0.0258%
$1.38$75,900-11.01%
2024-05-31PurchaseChief Financial Officer
25,006
0.0119%
$1.40$35,007-11.01%
2024-05-29Purchasedirector
30,031
0.0136%
$1.33$40,014-8.96%
2024-03-06Purchase10 percent owner
60.43M
19.5267%
$0.95$57.41M+24.02%
2024-01-30Purchasedirector
127,206
0.0309%
$0.71$90,710+64.51%
2024-01-29Purchasedirector
25,266
0.0055%
$0.64$16,170+83.63%
2024-01-26Purchasedirector
110,613
0.0212%
$0.56$62,304+97.44%
2024-01-25Purchasedirector
22,134
0.0037%
$0.49$10,846+140.08%
2024-01-24PurchaseChief Medical Officer
280,000
0.0476%
$0.50$139,888+152.35%
2024-01-24Purchasedirector
29,862
0.005%
$0.49$14,632+152.35%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.